TCIM
TBPH icon

TIAA CREF Investment Management’s Theravance Biopharma TBPH Stock Holding History

TIAA CREF Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.85M Buy
169,910
+2,539
+2% +$64.4K ﹤0.01% 1606
2018
Q4 		$4.28M Buy
167,371
+8,405
+5% +$227K ﹤0.01% 1474
2018
Q3 		$5.19M Buy
158,966
+34,495
+28% +$940K ﹤0.01% 1533
2018
Q2 		$2.82M Sell
124,471
-341
-0.3% -$8.1K ﹤0.01% 1984
2018
Q1 		$3.03M Sell
124,812
-1,037
-0.8% -$28.5K ﹤0.01% 1872
2017
Q4 		$3.51M Sell
125,849
-7,417
-6% -$219K ﹤0.01% 1823
2017
Q3 		$4.56M Sell
133,266
-20,892
-14% -$683K ﹤0.01% 1686
2017
Q2 		$6.14M Buy
154,158
+27,472
+22% +$1.06M ﹤0.01% 1462
2017
Q1 		$4.67M Sell
126,686
-8,815
-7% -$282K ﹤0.01% 1637
2016
Q4 		$4.32M Buy
135,501
+13,100
+11% +$406K ﹤0.01% 1703
2016
Q3 		$4.44K Sell
122,401
-2,518
-2% -$70.1K ﹤0.01% 1685
2016
Q2 		$2.83M Buy
124,919
+38,140
+44% +$824K ﹤0.01% 1918
2016
Q1 		$1.63M Buy
86,779
+5,375
+7% +$87.9K ﹤0.01% 2203
2015
Q4 		$1.33M Sell
81,404
-3,412
-4% -$54.1K ﹤0.01% 2405
2015
Q3 		$932K Buy
84,816
+1,369
+2% +$17.4K ﹤0.01% 2603
2015
Q2 		$1.09M Sell
83,447
-484
-0.6% -$7.51K ﹤0.01% 2652
2015
Q1 		$1.46M Hold
83,931
– – ﹤0.01% 2423
2014
Q4 		$1.25M Sell
83,931
-23,812
-22% -$415K ﹤0.01% 2533
2014
Q3 		$2.48M Sell
107,743
-11,635
-10% -$338K ﹤0.01% 2092
2014
Q2 		$3.81M Buy
+119,378
New +$3.59M ﹤0.01% 1871

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's TBPH Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Theravance Biopharma (TBPH) stake by 1.5% in Q1 2019, buying an estimated $64.4K and bringing the position to 169,910 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

TIAA CREF Investment Management first reported a position in TBPH in Q2 2014 and has held it in 20 quarters since. The position peaked at $6.14M in Q2 2017. 104 funds tracked by Wall St. Rank hold TBPH as of Q1 2019.

  • TIAA CREF Investment Management held 169,910 shares of Theravance Biopharma worth $3.85M as of Q1 2019.
  • TIAA CREF Investment Management bought 2,539 Theravance Biopharma shares in Q1 2019, an estimated $64.4K.
  • Theravance Biopharma made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1606 holding.
  • TIAA CREF Investment Management first reported a position in Theravance Biopharma in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Theravance Biopharma position peaked at $6.14M in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.